Pactiv Evergreen announces expiration of Hart-Scott-Rodino waiting period

Written by Emily J. Thompson, Senior Investment Analyst

PTVE%

Updated: Jan 21 2025

0mins

Acquisition Announcement: Pactiv Evergreen's waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has expired, allowing its acquisition by Novolex for $18.00 per share in cash to proceed.
Future of Pactiv Evergreen: The transaction is expected to close in the second quarter of 2025, after obtaining foreign antitrust approvals, and will result in Pactiv Evergreen becoming a privately held company with its stock delisted from Nasdaq.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Pactiv Evergreen announces expiration of Hart-Scott-Rodino waiting period

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Top Growth Stocks to Buy Now: Nvidia, Amazon, Dutch Bros

Bitcoin's Market Cap Exceeds $1.9 Trillion, Potential to Reach $1.2 Million

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch